A first‐in‐human, randomized, double‐blind, single‐ and multiple‐dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers

The study evaluated the safety, tolerability, pharmacokinetics (PK) and anti‐drug antibody (ADA) of the recombinant human thymosin β4 (NL005) for single and multiple intravenous injections in healthy subjects. Seven cohorts, with 54 healthy subjects, were given a single intravenous dose of NL005 or...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xinghe, Liu, Long, Qi, Lu, Lei, Chunpu, Li, Pu, Wang, Yu, Liu, Chen, Bai, Haihong, Han, Chengquan, Sun, Yinjian, Liu, Jincan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419156/
https://www.ncbi.nlm.nih.gov/pubmed/34346165
http://dx.doi.org/10.1111/jcmm.16693

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419156/
https://www.ncbi.nlm.nih.gov/pubmed/34346165
http://dx.doi.org/10.1111/jcmm.16693

Ejemplares similares